TOP

Raw Materials for Influenza A/B Antigen Detection (Lateral Flow Platform)

Date: 2020-09-30
Views: 314

There are an estimated 1 billion flu cases annually around the world according to WHO. Giving the early symptoms manifested by flu and COVID-19 are similar, tests for differentiation will be significant to enable accurate diagnosis and treatment. With the possible COVID-19 resurgence in winter, demands for flu and COVID-19 testing will be jumped high in parallel.

Health authorities and Dx companies already rolled out strategies and products in preparation for increasing needs of flu and COVID-19 testing. 
The Department of Health and Social Care of the UK has deployed new multiplex tests to differentiate flu and COVID-19 in hospitals, care houses, and labs since mid-August. Several companies introduced FDA and CE-cleared multiplex test panels for SARS-CoV-2, flu A/B, and RSV. Companies in the US aim to double testing capacity to serve millions of people who will line up for testing flu and COVID-19. Testing providers such as Fulgent Genetics offers influenza A/B test results to patients who test for COVID-19 throughout the winter.

However, current multiplex tests for flu and COVID-19 are mostly based on RT-PCR technology, which has disadvantages of cost, detection time and requirement of laboratory settings. Therefore, pushing combo Flu/COVID-19 test kits that can be performed directly in clinics and surveillant areas can unlock new business opportunities.


Raw Materials for Influenza A/B Antigen Detection (Lateral Flow Platform)


Raw Materials for Influenza A/B Antigen Detection (Lateral Flow Platform)     Raw Materials for Influenza A/B Antigen Detection (Lateral Flow Platform)     Raw Materials for Influenza A/B Antigen Detection (Lateral Flow Platform)    Raw Materials for Influenza A/B Antigen Detection (Lateral Flow Platform)




Product Features


  • Validated by the NIBSC & newly released China CDC influenza panels

  • Excellent reactivity & specificity

  • No cross-reaction to other respiratory diseases


*NIBSC refers to The National Institute for Biological Standards and Control that supplies international biological standards and other biological reference materials to WHO for influenza test standardization. China CDC refers to the Chinese Center for Disease Control and Prevention


Featured Antibody Pairs (Lateral Flow Platform)


Product

Pair No.

Catalog No.

Source

Clone

Isotype

Application

Blocker

Influenza A

Pair 1

BRCINFS102

CHO

31B4

IgG1

Coating

BRJINFS102

CHO

30C6

IgG2a

Conjugate

Pair 2

BRJINFS102

CHO

30C6

IgG2a

Coating

BRCINFS102

CHO

31B4

IgG1

Conjugate

Pair 3

BRCINFS103

CHO

30A5

IgG2a

Coating

BRCINFS102

CHO

31B4

IgG1

Conjugate

Influenza B

Pair 1

BRNINFJ203

CHO

30D4

IgG2a

Coating

BRNINFC202

CHO

30E3

IgG1

Conjugate

Pair 2

BRNINFC201

Mouse

2F3

IgM

Coating

BRNINFJ204

CHO

30E2

IgG2b

Conjugate

Pair 3

BRNINFJ203

CHO

30D4

IgG2a

Coating

BRNINFC201

Mouse

2F3

IgM

Conjugate


Performance


Reactivity-Influenza A Antibody Pairs


Sample Info

Reactivity

Source

Type of Virus

Viral Strain

Dilution Ration

Pair 1

Pair 2

Pair 3

Fapon Quality Control

Cultured-based Virus

H1N1

1:500

C2

C3+

C3+

1:5000

C5+

C5

C5

1:50000

C7

C8+

C8+

H3N2

1:500

C1

C1

C1

1:5000

C3

C3

C3

1:50000

C5+

C5

C5

H5N1

1:20

C2

C3+

C3+

1:200

C6+

C6

C6

1:2000

C8+

C9+

C9+

H7N9

1:20

C2+

C2

C2

1:200

C5+

C5

C5

1:2000

C7

C8

C8

NIBSC Standard

Inactivated Virus

Influenza Virus Infectious NYMC X-185

20

C1+

C1+

C1+

1000

C6

C7

C7

Influenza Virus infectious Resvir-14 (H3N2)

20

C2

C3

C3

1000

C8

C9

C9

Influenza Virus infectious NIB-26 (H3N2)

20

C2+

C2

C2

1000

C7

C9+

C9+

Influenza Antigen A/Texas/50/2012 (NYMC X-223A)

20

C6

-

-

1000

C9+

C9+

C9+

Influenza Virus infectious A/Beijing/32/92 (H3N2)

20

C1

C2+

C2+

1000

C7

C8+

C8+

Influenza Virus infectious A/Shanghai/24/90

20

C1

C2

C2

1000

C7

C8

C8

Influenza Virus infectious A/Sichuan/346/98 (H3N2)

20

C1

C1

C1

1000

C8+

C8

C8

Others

2019/H3N2

20

C1

C2+

C2+

2019/H1N1

20

C1

C2

C2

2019/H1N1

20

C1

C1

C1

A/Brisbane/10/2007

-

Detectable

A/Perth/16/2009

A/California/7/2004

A/Brisbane/59/2007

A/Victoria/361/2011

A/California/7/2009

A/New Caledonia/20/1999

A/Wisconsin/67/2005

A/Solomon Islands/3/2006

H1N1 Virus

A/Taiwan/1/86(8IN73)

A/Beijing/262/95(8IN73-2)

Influenza Virus infectious A/Guizhou/54/89 (H3N2)

Influenza Virus infectious A/Wuhan/359/95 (H3N2

H3N2 Virus

A/Victoria/210/2009w

A/Kiev/301/94(8IN74-2)

H3N2 A/Panama/2007/998IN74-1

A/Shandong/9/93(8IN74)

A/Texas/50/2012

A/Hiroshima/52/2005


Reactivity-Influenza B Antibody Pairs


Sample Info

Reactivity

Source

Type of Virus

Viral Strain

Dilution Ration

Pair 1

Pair 2

Pair 3

Fapon Quality Control

Cultured-based Virus

Influenza B Quality Control

30

C4

C4+

C4

300

C6

C6+

C6

3000

C8

C8+

C8

NIBSC Standard

Inactivated Virus

Influenza Virus infectious NYMC BX-7

20

C4

C4+

C4+

1000

C9

C9

C9

Influenza virus infectious NYMC BX-39

20

C3

C3+

C3

1000

C8+

C8+

C8+

Others

BY-V1908875256

32

C4

C3

C4+

640

C6

C5

C6+

BV-V1906106179

64

C5

C5+

C5

640

C7

C7+

C7

BV-V1906106180

100

C7

C7

C7

1000

C9

C9

C9

BV-V1906106181

100

C6

C7

C7

1000

C8

C9

C9

BV-V1906106182

100

C5

C6+

C6

1000

C8

C8

C8

B/Shanghai/361/02

-

Detectable

B/Malaysia/2506/2004

B/Massachusetts/2/2012

B/Wisconsin/01/2010

B/Tokio/53/99

Influenza Virus infectious B/Sichuan/379/99

B/Qingdao/102/91

B/Brisbane/60/2008

B/Florida/04/2006

B/Victoria/504/00

Influenza Virus infectious B/Shanghai/361/2002


Raw Materials for Influenza A/B Antigen Detection (Lateral Flow Platform)

Result interpretation: the higher the number, the lower the activity, B refers to undetectable


Cross-Reactivity

Tested Fapon Influenza A/B antibodies with SARS-CoV-2, Mycoplasma Pneumoniae, Parainfluenza, RSV, Adenovirus and other viral pathogens at different concentrations, results showed no detection, suggesting no cross-reaction and false-positive results.


Type of Pathogen

Pathogen

Type of Virus

Concentration

Result

SARS-CoV-2

S/ N Protein

Recombinant antigen

10 μg/mL

No cross-reaction with Influenza A/B

Cultured-based virus

1:200 Dilution

Mycoplasma Pneumoniae

Mycoplasma pneumonia

Inactivated virus

50 μg/mL

Parainfluenza

Parainfluenza 2

5 μg/mL

RSV

RSV

50 μg/mL

Adenovirus

Adenoviridae

10 μg/mL

Influenza B

Influenza B virus

Cultured-based virus

55 μg/mL

No cross-reaction with Influenza

Influenza A H1N1

Influenza A virus

2 μg/mL

No cross-reaction with Influenza A

Influenza A H3N2

36 μg/mL

Influenza A H5N1

15 μg/mL

Influenza A H7N9

40 μg/mL

Others

EB virus

Inactivated virus

30 μg/mL

No cross-reaction with Influenza A/B

Mumps virus

50 μg/mL

Varicella-zoster virus

50 μg/mL

Human cytomegalovirus

1:10 Dilution

Measles virus

1:10 Dilution

Rotavirus

1:10 Dilution



Specificity

Tested Fapon Influenza A & B Antibody Pairs and Combo (Influenza A Pair 1 + Influenza B Antibody Pair 2) respectively with 106 clinical throat swab samples, results showed 100% specificity, no false-positive results.


Stability

Fapon Influenza Antibody Pairs showed little changes in activity and specificity levels in different temperature, storage periods, and repeated freezing/thawing at 18 times, confirming excellent product stability.


Temperature (C°)

Evaluation Period (Days)

-80

21

-20

21

-4

21

Room Temperature

7/14/21

37

7/14/21

45

7








  form>